mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2024-3-78-84mrj-1592Research ArticleОБЗОРЫREVIEWSОсобенности применения внутривенных иммуноглобулинов при ревматических заболеванияхPeculiar features of intravenous immunoglobulins application in rheumatic diseaseshttps://orcid.org/0000-0002-4846-5531ЕгороваО. Н.EgorovaO. N.

Ольга Николаевна Егорова

115522; Каширское шоссе, 34А; Москва

Olga Nikolaevna Egorova

115522; 34A, Kashirskoye Shosse; Moscow

onegorova@yandex.ruhttps://orcid.org/0000-0001-9933-5350ТарасоваГ. М.TarasovaG. M.

115522; Каширское шоссе, 34А; Москва

115522; 34A, Kashirskoye Shosse; Moscow

https://orcid.org/0000-0003-3051-219XДацинаА. В.DatsinaA. V.

115522; Каширское шоссе, 34А; Москва

115522; 34A, Kashirskoye Shosse; Moscow

https://orcid.org/0000-0001-9797-0182СажинаЕ. Г.SazhinaE. G.

115522; Каширское шоссе, 34А; Москва

115522; 34A, Kashirskoye Shosse; Moscow

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation2024150620241837884Copyright © Егорова О.Н., Тарасова Г.М., Дацина А.В., Сажина Е.Г., 20242024Егорова О.Н., Тарасова Г.М., Дацина А.В., Сажина Е.Г.Egorova O.N., Tarasova G.M., Datsina A.V., Sazhina E.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1592

   Внутривенные иммуноглобулины (ВВИГ) – наиболее широко применяемые иммунобиологические средства, которые вырабатываются из донорской крови. Впервые они были использованы в середине ХХ в. для лечения первичных иммунодефицитов. Позднее их начали успешно применять при различных аутоиммунных, воспалительных и других заболеваниях. В настоящее время растет число фундаментальных и клинических исследований, посвященных механизму действия и эффективности разных доз ВВИГ. В то же время многое остается неясным, противоречивым, а некоторые данные и вовсе носят взаимоисключающий характер.

   Intravenous immunoglobulins (IVIG) are the most commonly used immunobiological agents produced from donor blood. They were first used in the mid-twentieth century for the treatment of primary immunodeficiencies. Later, they were successfully used to treat a variety of autoimmune, inflammatory and other diseases. There are currently a growing number of basic and clinical studies looking at the mechanism of action and efficacy of different doses of IVIG. At the same time, much remains unclear, contradictory, and some data are mutually exclusive.

внутривенные иммуноглобулиныревматические заболеванияпоказания к назначениювысокие и низкие дозыintravenous immunoglobulinsrheumatic diseasesindications for usehigh and low dosesСтатья подготовлена в рамках научно-исследовательской работы, № государственного задания РК 122040400024-7. Исследование не имело спонсорской поддержкиThe article was prepared within the framework of a research work, №/№ of state assignments РК 122040400024-7. The investigation has not been sponsoredReferencesBayry J, Misra N, Latry V et al. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Transfus Clin Biol. 2003 Jun;10(3):165-9. doi: 10.1016/s1246-7820(03)00035-1.Bayry J, Misra N, Latry V et al. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Transfus Clin Biol. 2003 Jun;10(3):165-9. doi: 10.1016/s1246-7820(03)00035-1.Greenberg M, Frant S, Rutstein D. «Gammaglobulin» and «placental globulin»; comparison of their effectiveness in prevention and modification of measles. JAMA. 1944;126(15): 944-47.Greenberg M, Frant S, Rutstein D. «Gammaglobulin» and «placental globulin»; comparison of their effectiveness in prevention and modification of measles. JAMA. 1944;126(15): 944-47.Ordman CW, Jennings JR, Janeway CA. Chemical, Clinical and Immunological studies on the products of human plasma fractionation. XII. The Use of Concentrated Normal Human Serum Gamma Globulin (Human Immune Serum Globulin) in the Prevention and Attenuation of Measles. J Clin Invest. 1944 Jul;23(4):541-9. doi: 10.1172/JCI101519.Ordman CW, Jennings JR, Janeway CA. Chemical, Clinical and Immunological studies on the products of human plasma fractionation. XII. The Use of Concentrated Normal Human Serum Gamma Globulin (Human Immune Serum Globulin) in the Prevention and Attenuation of Measles. J Clin Invest. 1944 Jul;23(4):541-9. doi: 10.1172/JCI101519.Stokes J, Neefe J. The prevention and attenuation of infectious hepatitis by gamma globulin. Preliminary note. JAMA.1945;127(3): 144-45.Stokes J, Neefe J. The prevention and attenuation of infectious hepatitis by gamma globulin. Preliminary note. JAMA.1945;127(3): 144-45.Вruton O. Agammaglobulinemia. Pediatrics.1952;(9):722-28.Вruton O. Agammaglobulinemia. Pediatrics.1952;(9):722-28.Imbach P, Barandun S, Baumgartner C, et al.High-dose intravenous gamma globulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv Paediatr Acta. 1981 Feb;36(1):81-6.Imbach P, Barandun S, Baumgartner C, et al.High-dose intravenous gamma globulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv Paediatr Acta. 1981 Feb;36(1):81-6.Saeedian M, Randhawa I. Immunoglobulin replacement therapy: a twenty-year review and current update. Int Arch Allergy Immunol. 2014;164(2):151-66. doi: 10.1159/000363445. Epub 2014 Jul 10.Saeedian M, Randhawa I. Immunoglobulin replacement therapy: a twenty-year review and current update. Int Arch Allergy Immunol. 2014;164(2):151-66. doi: 10.1159/000363445. Epub 2014 Jul 10.Wood JG, Heywood AE, Dennington PM, et al. Trends in intravenous immunoglobulin use in New South Wales, Australia. Intern Med J. 2024 Jan;54(1):149-156. doi: 10.1111/imj.16175.Wood JG, Heywood AE, Dennington PM, et al. Trends in intravenous immunoglobulin use in New South Wales, Australia. Intern Med J. 2024 Jan;54(1):149-156. doi: 10.1111/imj.16175.Velikova T, Sekulovski M, Bogdanova S, et al. Intravenous immunoglobulins as immunomodulators in autoimmune diseases and reproductive medicine. Antibodies (Basel). 2023 Mar 2;12(1):20. doi: 10.3390/antib12010020.Velikova T, Sekulovski M, Bogdanova S, et al. Intravenous immunoglobulins as immunomodulators in autoimmune diseases and reproductive medicine. Antibodies (Basel). 2023 Mar 2;12(1):20. doi: 10.3390/antib12010020.National Blood Authority. National report on the issue and use of immunoglobulin (IVIg). Annual report 2015–16. Canberra: Common-wealth of Australia; 2017. https://www.blood.gov.au/data-analysis-reporting.National Blood Authority. National report on the issue and use of immunoglobulin (IVIg). Annual report 2015–16. Canberra: Common-wealth of Australia; 2017. https://www.blood.gov.au/data-analysis-reporting.Tavee J, Brannagan TH 3<sup>rd</sup>, Lenihan MW, et al. Updated consensus statement: Intravenous immunoglobulin in the treatment of neuromuscular disorders report of the AANEM ad hoc committee. Muscle Nerve. 2023 Oct; 68(4):356-74. doi: 10.1002/mus.27922.Tavee J, Brannagan TH 3<sup>rd</sup>, Lenihan MW, et al. Updated consensus statement: Intravenous immunoglobulin in the treatment of neuromuscular disorders report of the AANEM ad hoc committee. Muscle Nerve. 2023 Oct; 68(4):356-74. doi: 10.1002/mus.27922.Danieli MG, Antonelli E, Auria SS, et al. Low-dose intravenous immunoglobulin (IVIg) in different immune-mediated conditions. Autoimmun Rev. 2023 Nov; 22(11):103451. doi: 10.1016/j.autrev.2023.103451.Danieli MG, Antonelli E, Auria SS, et al. Low-dose intravenous immunoglobulin (IVIg) in different immune-mediated conditions. Autoimmun Rev. 2023 Nov; 22(11):103451. doi: 10.1016/j.autrev.2023.103451.Hadaschik E, Eming R, French LE, et al. European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology. Hautarzt. 2020 Jul;71(7):542-52. doi: 10.1007/s00105-020-04610-6.Hadaschik E, Eming R, French LE, et al. European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology. Hautarzt. 2020 Jul;71(7):542-52. doi: 10.1007/s00105-020-04610-6.Середавкина НВ, Решетняк ТМ, Насонов ЕЛ. Место внутривенного иммуноглобулина при ревматических заболеваниях. Современная ревматология. 2015;9(4):59-67. doi:10.14412/1996-7012-2015-4-59-67.Seredavkina NV, Reshetnyak TM, Nasonov EL. The place of intravenous immunoglobulin in rheumatic diseases. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2015;9(4):59-67. (In Russ.). doi:10.14412/1996-7012-2015-4-59-67.Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med. 2012 Nov 22;367(21):2015-25. doi: 10.1056/NEJMra1009433.Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med. 2012 Nov 22;367(21):2015-25. doi: 10.1056/NEJMra1009433.Лазанович ВА, Просекова ЕВ. Внутривенные иммуноглобулины: механизмы терапевтических эффектов. Медицинская иммунология. 2014;16(4):311-22.Lazanovich VA, Prosekova EV. Intravenous immunoglobulins: mechanisms of therapeutic effects. Meditsinskaya immunologiya. 2014; 16(4):311-22. (In Russ.)Shoenfeld Y, Gershwin ME. Intravenous immunoglobulin. Clinic Rev Allerg Immunol. 2005;29:165-66. doi:10.1385/CRIAI:29:3:165.Shoenfeld Y, Gershwin ME. Intravenous immunoglobulin. Clinic Rev Allerg Immunol. 2005;29:165-66. doi:10.1385/CRIAI:29:3:165.Bayry J,Fournier EM, Maddur MS, et al. Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: A mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J Autoimmun. 2011 Feb;36(1): 9-15. doi: 10.1016/j.jaut.2010.09.006. Epub 2010 Dec 9.Bayry J,Fournier EM, Maddur MS, et al. Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: A mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J Autoimmun. 2011 Feb;36(1): 9-15. doi: 10.1016/j.jaut.2010.09.006. Epub 2010 Dec 9.Maddur MS, Kaveri SV, Bayry J. Comparison of different IVIg preparations on IL-17 production by human Th17 cells. Autoimmun Rev. 2011 Oct;10(12):809-10. doi: 10.1016/j.autrev.2011.02.007. Epub 2011 Mar 2.Maddur MS, Kaveri SV, Bayry J. Comparison of different IVIg preparations on IL-17 production by human Th17 cells. Autoimmun Rev. 2011 Oct;10(12):809-10. doi: 10.1016/j.autrev.2011.02.007. Epub 2011 Mar 2.Blank M, Bashi T, Shoenfeld Y. Idiotype-specific intravenous immunoglobulin (IVIG) for therapy of autoimmune diseases. Methods Mol Biol. 2014:1060:353-61. doi: 10.1007/978-1-62703-586-6_18.Blank M, Bashi T, Shoenfeld Y. Idiotype-specific intravenous immunoglobulin (IVIG) for therapy of autoimmune diseases. Methods Mol Biol. 2014:1060:353-61. doi: 10.1007/978-1-62703-586-6_18.Hulett MD, Hogarth PM. Molecular Basis of Fc Receptor Function. Adv Immunol. 1994; 57:1-127. doi: 10.1016/s0065-2776(08)60671-9.Hulett MD, Hogarth PM. Molecular Basis of Fc Receptor Function. Adv Immunol. 1994; 57:1-127. doi: 10.1016/s0065-2776(08)60671-9.Spahn JD, Leung DY, Chan MT, et al. Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intravenous immunoglobulin. J Allergy Clin Immunol. 1999 Mar;103(3 Pt 1):421-6. doi: 10.1016/s0091-6749(99)70466-5.Spahn JD, Leung DY, Chan MT, et al. Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intravenous immunoglobulin. J Allergy Clin Immunol. 1999 Mar;103(3 Pt 1):421-6. doi: 10.1016/s0091-6749(99)70466-5.Zandman-Goddard G, Krauthammer A, Levy Y, et al. Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases. Clin Rev Allergy Immunol. 2012 Apr;42(2):247-55. doi: 10.1007/s12016-011-8278-7.Zandman-Goddard G, Krauthammer A, Levy Y, et al. Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases. Clin Rev Allergy Immunol. 2012 Apr;42(2):247-55. doi: 10.1007/s12016-011-8278-7.Dalakas MC. Update on intravenous immunoglobulin in neurology: modulating neuro-autoimmunity, evolving factors on efficacy and dosing and challenges on stopping chronic IVIg therapy. Neurotherapeutics. 2021 Oct;18(4):2397-2418. doi: 10.1007/s13311-021-01108-4. Epub 2021 Nov 11.Dalakas MC. Update on intravenous immunoglobulin in neurology: modulating neuro-autoimmunity, evolving factors on efficacy and dosing and challenges on stopping chronic IVIg therapy. Neurotherapeutics. 2021 Oct;18(4):2397-2418. doi: 10.1007/s13311-021-01108-4. Epub 2021 Nov 11.Benavides-Villanueva F, Loricera J, Calvo-Rio V, et al, Intravenous immunoglobulin therapy in antineutrophil cytoplasmic antibody-associated vasculitis. Eur J Intern Med. 2023 Nov;117:78-84. doi: 10.1016/j.ejim.2023.06.021.Benavides-Villanueva F, Loricera J, Calvo-Rio V, et al, Intravenous immunoglobulin therapy in antineutrophil cytoplasmic antibody-associated vasculitis. Eur J Intern Med. 2023 Nov;117:78-84. doi: 10.1016/j.ejim.2023.06.021.Yates M, Watts AR, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016 Sep;75(9):1583-94. doi: 10.1136/annrheumdis-2016-209133. Epub 2016 Jun 23.Yates M, Watts AR, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016 Sep;75(9):1583-94. doi: 10.1136/annrheumdis-2016-209133. Epub 2016 Jun 23.Katz U, Achiron A, Sherer Y, et al. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev. 2007 Mar;6(4):257-9. doi: 10.1016/j.autrev.2006.08.011. Epub 2006 Aug 28.Katz U, Achiron A, Sherer Y, et al. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev. 2007 Mar;6(4):257-9. doi: 10.1016/j.autrev.2006.08.011. Epub 2006 Aug 28.Aggarwal R, Schessl J, Charles-Schoeman C, et al. Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study. Arthritis Res Ther. 2024 Jan 17;26(1):27. doi: 10.1186/s13075-023-03232-2.Aggarwal R, Schessl J, Charles-Schoeman C, et al. Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study. Arthritis Res Ther. 2024 Jan 17;26(1):27. doi: 10.1186/s13075-023-03232-2.Zandman-Goddard G, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy and systemic lupus erythematosus. Clin Rev Allergy Immunol. 2005 Dec;29(3):219-28. doi: 10.1385/CRIAI:29:3:219.Zandman-Goddard G, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy and systemic lupus erythematosus. Clin Rev Allergy Immunol. 2005 Dec;29(3):219-28. doi: 10.1385/CRIAI:29:3:219.Toubi E, Kessel A, Shoenfeld Y. High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Hum Immunol. 2005 Apr;66(4):395-402. doi: 10.1016/j.humimm.2005.01.022.Toubi E, Kessel A, Shoenfeld Y. High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Hum Immunol. 2005 Apr;66(4):395-402. doi: 10.1016/j.humimm.2005.01.022.Sherer Y, Kuechler S, Jose Scali J, et al. Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases. Isr Med Assoc J. 2008 Jan;10(1):55-7.Sherer Y, Kuechler S, Jose Scali J, et al. Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases. Isr Med Assoc J. 2008 Jan;10(1):55-7.Binello N, Cancelli C, Passalacqua S, et al. Use of intravenous immunoglobulin therapy at unconventional doses in refractory fulminant systemic lupus erythematosus. Eur J Case Rep Intern Med. 2018 Sep 27;5(9):000934. doi: 10.12890/2018_000934. eCollection 2018.Binello N, Cancelli C, Passalacqua S, et al. Use of intravenous immunoglobulin therapy at unconventional doses in refractory fulminant systemic lupus erythematosus. Eur J Case Rep Intern Med. 2018 Sep 27;5(9):000934. doi: 10.12890/2018_000934. eCollection 2018.Schroeder J, Zeuner AR, Euler HH, Lцffler H. High dose intravenous immunoglobulins in systemic lupus erythematosus: Clinical and serological results of a pilot study. J Rheumatol. 1996 Jan;23(1):71-5.Schroeder J, Zeuner AR, Euler HH, Lцffler H. High dose intravenous immunoglobulins in systemic lupus erythematosus: Clinical and serological results of a pilot study. J Rheumatol. 1996 Jan;23(1):71-5.Levy Y, Sherer Y, Ahmed A, et al. A study of 20 SLE patients with intravenous immunoglobulin clinical and serologic response. Lupus. 1999;8(9):705-12. doi: 10.1191/096120399678841007.Levy Y, Sherer Y, Ahmed A, et al. A study of 20 SLE patients with intravenous immunoglobulin clinical and serologic response. Lupus. 1999;8(9):705-12. doi: 10.1191/096120399678841007.Tenti S, Cheleschi S, Guidelli GM, et al. Intravenous immunoglobulins and antiphospholipid syndrome: How, when and why? A review of the literature. Autoimmun Rev. 2016 Mar;15(3):226-35. doi: 10.1016/j.autrev.2015.11.009. Epub 2015 Dec 1.Tenti S, Cheleschi S, Guidelli GM, et al. Intravenous immunoglobulins and antiphospholipid syndrome: How, when and why? A review of the literature. Autoimmun Rev. 2016 Mar;15(3):226-35. doi: 10.1016/j.autrev.2015.11.009. Epub 2015 Dec 1.Sciascia S, Giachino O, Roccatello D. Prevention of thrombosis relapse in anti-phospholipid syndrome patients refractory to conventional therapy using intravenous immunoglobulin. Clin Exp Rheumatol. 2012 May-Jun;30(3):409-13. Epub 2012 Jun 26.Sciascia S, Giachino O, Roccatello D. Prevention of thrombosis relapse in anti-phospholipid syndrome patients refractory to conventional therapy using intravenous immunoglobulin. Clin Exp Rheumatol. 2012 May-Jun;30(3):409-13. Epub 2012 Jun 26.Ruiz-Irastorza G, Espinosa G, Frutos M, et al. Diagnosis and treatment of lupus nephritis: Consensus document from the systemic autoimmune disease group (GEAS) of the Spanish Society of Internal Medicine (SEMI) and the Spanish Society of Nephrology (S.E.N.). Nefrologia. 2012:32 Suppl 1:1-35. doi: 10.3265/Nefrologia.pre2011.Dec.11298.Ruiz-Irastorza G, Espinosa G, Frutos M, et al. Diagnosis and treatment of lupus nephritis: Consensus document from the systemic autoimmune disease group (GEAS) of the Spanish Society of Internal Medicine (SEMI) and the Spanish Society of Nephrology (S.E.N.). Nefrologia. 2012:32 Suppl 1:1-35. doi: 10.3265/Nefrologia.pre2011.Dec.11298.Caccavo D, Vaccaro F, Ferri GM, et al. Antiidiotypes against antiphospholipid anti-bodies are present in normal polyspecific immunoglobulins for therapeutic use. J Autoimmun. 1994 Aug;7(4):537-48. doi: 10.1006/jaut.1994.1039.Caccavo D, Vaccaro F, Ferri GM, et al. Antiidiotypes against antiphospholipid anti-bodies are present in normal polyspecific immunoglobulins for therapeutic use. J Autoimmun. 1994 Aug;7(4):537-48. doi: 10.1006/jaut.1994.1039.Horn HC, Grau K, Junker P. IVIG treatment for progressive stroke in the primary antiphospholipid antibody syndrome. Lupus. 2004;13(6):478-80. doi: 10.1191/0961203303lu1035cr.Horn HC, Grau K, Junker P. IVIG treatment for progressive stroke in the primary antiphospholipid antibody syndrome. Lupus. 2004;13(6):478-80. doi: 10.1191/0961203303lu1035cr.Mulhearn B, Bruce IN. Indications for IVIG in rheumatic diseases. Rheumatology (Oxford). 2015 Mar;54(3):383-91. doi: 10.1093/rheumatology/keu429. Epub 2014 Nov 17.Mulhearn B, Bruce IN. Indications for IVIG in rheumatic diseases. Rheumatology (Oxford). 2015 Mar;54(3):383-91. doi: 10.1093/rheumatology/keu429. Epub 2014 Nov 17.Bitsadze V, Yakubova F, Khizroeva J, et al. Catastrophic Antiphospholipid Syndrome. Int J Mol Sci. 2024 Jan 4; 25(1):668. doi: 10.3390/ijms25010668.Bitsadze V, Yakubova F, Khizroeva J, et al. Catastrophic Antiphospholipid Syndrome. Int J Mol Sci. 2024 Jan 4; 25(1):668. doi: 10.3390/ijms25010668.Marie I, Menard JF, Hatron PY, et al. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: A series of 73 patients. Arthritis Care Res (Hoboken). 2010 Dec;62(12):1748-55. doi: 10.1002/acr.20325.Marie I, Menard JF, Hatron PY, et al. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: A series of 73 patients. Arthritis Care Res (Hoboken). 2010 Dec;62(12):1748-55. doi: 10.1002/acr.20325.Suzuki Y, Hayakawa H, Miwa S, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung. 2009 May-Jun;187(3):201-6. doi: 10.1007/s00408-009-9146-6. Epub 2009 Apr 22.Suzuki Y, Hayakawa H, Miwa S, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung. 2009 May-Jun;187(3):201-6. doi: 10.1007/s00408-009-9146-6. Epub 2009 Apr 22.Cherin P, Pelletier S, Teixeira A, et al. Results and long-term follow-up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: An open study with thirty-five adult patients. Arthritis Rheum. 2002 Feb;46(2):467-74. doi: 10.1002/art.10053.Cherin P, Pelletier S, Teixeira A, et al. Results and long-term follow-up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: An open study with thirty-five adult patients. Arthritis Rheum. 2002 Feb;46(2):467-74. doi: 10.1002/art.10053.Speca S, Farhat MM, Jendoubi M, et al. Intravenous immunoglobulins improve skin fibrosis in experimental models of systemic sclerosis. Sci Rep. 2023 Sep 12;13(1):15102. doi: 10.1038/s41598-023-42464-9.Speca S, Farhat MM, Jendoubi M, et al. Intravenous immunoglobulins improve skin fibrosis in experimental models of systemic sclerosis. Sci Rep. 2023 Sep 12;13(1):15102. doi: 10.1038/s41598-023-42464-9.Tandaipan J, Guillen-Del-Castillo A, Simeуn-Aznar CP, et al. Immunoglobulins in systemic sclerosis management. A large multi-center experience. Autoimmun Rev. 2023 Nov; 22(11):103441. doi: 10.1016/j.autrev.2023.103441.Tandaipan J, Guillen-Del-Castillo A, Simeуn-Aznar CP, et al. Immunoglobulins in systemic sclerosis management. A large multi-center experience. Autoimmun Rev. 2023 Nov; 22(11):103441. doi: 10.1016/j.autrev.2023.103441.Matsuda KM, Yoshizaki A, Kuzumi A, et al. Rapid improvement of systemic sclerosis-associated intestinal pseudo-obstruction with intravenous immunoglobulin administration. Rheumatology (Oxford). 2023 Sep 1; 62(9):3139-45. doi: 10.1093/rheumatology/kead093.Matsuda KM, Yoshizaki A, Kuzumi A, et al. Rapid improvement of systemic sclerosis-associated intestinal pseudo-obstruction with intravenous immunoglobulin administration. Rheumatology (Oxford). 2023 Sep 1; 62(9):3139-45. doi: 10.1093/rheumatology/kead093.Blank M, Levy Y, Amital H, et al. The role of intravenous immunoglobulin therapy in mediating skin fibrosis in high skin mice. Arthritis Rheum. 2002 Jun;46(6):1689-90. doi: 10.1002/art.10363.Blank M, Levy Y, Amital H, et al. The role of intravenous immunoglobulin therapy in mediating skin fibrosis in high skin mice. Arthritis Rheum. 2002 Jun;46(6):1689-90. doi: 10.1002/art.10363.Richter C, Schnabel A, Csernok E, et al. Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol. 1995 Jul;101(1):2-7. doi: 10.1111/j.1365-2249.1995.tb02268.x.Richter C, Schnabel A, Csernok E, et al. Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol. 1995 Jul;101(1):2-7. doi: 10.1111/j.1365-2249.1995.tb02268.x.Aries PM, Hellmich B, Gross WL. Intravenous immunoglobulin therapy in vasculitis. Clin Rev Allergy Immunol. 2005 Dec;29(3): 237-45. doi: 10.1385/CRIAI:29:3:237.Aries PM, Hellmich B, Gross WL. Intravenous immunoglobulin therapy in vasculitis. Clin Rev Allergy Immunol. 2005 Dec;29(3): 237-45. doi: 10.1385/CRIAI:29:3:237.Kivity S, Katz U, Daniel N, et al. Evidence for the use of intravenous immunoglobulins – a review of the literature. Clin Rev Allergy Immunol. 2010 Apr;38(2-3):201-69. doi: 10.1007/s12016-009-8155-9.Kivity S, Katz U, Daniel N, et al. Evidence for the use of intravenous immunoglobulins – a review of the literature. Clin Rev Allergy Immunol. 2010 Apr;38(2-3):201-69. doi: 10.1007/s12016-009-8155-9.Chung SA, Langford CA, Maz M, et al. 2021 american college of rheumatology/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res (Hoboken). 2021 Aug;73(8):1088-1105. doi: 10.1002/acr.24634. Epub 2021 Jul 8.Chung SA, Langford CA, Maz M, et al. 2021 american college of rheumatology/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res (Hoboken). 2021 Aug;73(8):1088-1105. doi: 10.1002/acr.24634. Epub 2021 Jul 8.Hellmich В, Sanchez-Alamo В, Schirmer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024 Jan 2; 83(1):30-47. doi: 10.1136/ard-2022-223764.Hellmich В, Sanchez-Alamo В, Schirmer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024 Jan 2; 83(1):30-47. doi: 10.1136/ard-2022-223764.Jayne D, Chapel H, Adu D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM. 2000 Jul;93(7):433-9. doi: 10.1093/qjmed/93.7.433.Jayne D, Chapel H, Adu D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM. 2000 Jul;93(7):433-9. doi: 10.1093/qjmed/93.7.433.Shimizu T, Morita T, Kumanogoh A. The therapeutic efficacy of intravenous immunoglobulin in anti-neutrophilic cytoplasmic antibody-associated vasculitis: A meta-analysis. Rheumatology (Oxford). 2020 May 1; 59(5):959-967. doi: 10.1093/rheumatology/kez311.Shimizu T, Morita T, Kumanogoh A. The therapeutic efficacy of intravenous immunoglobulin in anti-neutrophilic cytoplasmic antibody-associated vasculitis: A meta-analysis. Rheumatology (Oxford). 2020 May 1; 59(5):959-967. doi: 10.1093/rheumatology/kez311.Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992 Mar 15;116(6): 488-98. doi: 10.7326/0003-4819-116-6-488.Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992 Mar 15;116(6): 488-98. doi: 10.7326/0003-4819-116-6-488.Martinez V, Cohen P, Pagnoux C, et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: Results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum. 2008 Jan;58(1):308-17. doi: 10.1002/art.23147.Martinez V, Cohen P, Pagnoux C, et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: Results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum. 2008 Jan;58(1):308-17. doi: 10.1002/art.23147.Fortin PM, Tejani AM, Bassett K, Musini V. Intravenous immunoglobulin as adjuvant therapy for Wegener’s granulomatosis. Cochrane Database Syst Rev. 2013 Jan 31;2013(1): CD007057. doi: 10.1002/14651858.CD007057.pub3.Fortin PM, Tejani AM, Bassett K, Musini V. Intravenous immunoglobulin as adjuvant therapy for Wegener’s granulomatosis. Cochrane Database Syst Rev. 2013 Jan 31;2013(1): CD007057. doi: 10.1002/14651858.CD007057.pub3.Weishaupt C, Strölin A, Kahle B, et al. Characteristics, risk factors and treatment reality in livedoid vasculopathy - a multicentre analysis. J Eur Acad Dermatol Venereol. 2019 Sep;33(9):1784-1791. doi: 10.1111/jdv.15639. Epub 2019 May 14.Weishaupt C, Strölin A, Kahle B, et al. Characteristics, risk factors and treatment reality in livedoid vasculopathy - a multicentre analysis. J Eur Acad Dermatol Venereol. 2019 Sep;33(9):1784-1791. doi: 10.1111/jdv.15639. Epub 2019 May 14.Ozden MG, Ozdemir H, Senturk N. Intravenous immunoglobulin in resistant livedoid vasculopathy: analysis of a case series. Dermatol Ther. 2020 Mar;33(2):e13229. doi: 10.1111/dth.13229. Epub 2020 Feb 4.Ozden MG, Ozdemir H, Senturk N. Intravenous immunoglobulin in resistant livedoid vasculopathy: analysis of a case series. Dermatol Ther. 2020 Mar;33(2):e13229. doi: 10.1111/dth.13229. Epub 2020 Feb 4.Kofler K, Strölin A, Geiger V, Kofler L. Intravenous immunoglobulin therapy in livedoid vasculopathy: retrospective observation of clinical outcome and patient's activity level. J Cutan Med Surg. 2021 Sep;25(5):504-10. doi: 10.1177/12034754211003525.Kofler K, Strölin A, Geiger V, Kofler L. Intravenous immunoglobulin therapy in livedoid vasculopathy: retrospective observation of clinical outcome and patient's activity level. J Cutan Med Surg. 2021 Sep;25(5):504-10. doi: 10.1177/12034754211003525.Cantarini L, Stromillo ML, Vitale A, et al. Efficacy and Safety of Intravenous Immunoglobulin Treatment in Refractory Behcet's Disease with Different Organ Involvement: A Case Series. Isr Med Assoc J. 2016 Mar-Apr;18 (3-4):238-42.Cantarini L, Stromillo ML, Vitale A, et al. Efficacy and Safety of Intravenous Immunoglobulin Treatment in Refractory Behcet's Disease with Different Organ Involvement: A Case Series. Isr Med Assoc J. 2016 Mar-Apr;18 (3-4):238-42.Seeliger T, Prenzler NK, Gingele S, et al. Neuro-Sjцgren: Peripheral Neuropathy With Limb Weakness in Sjцgren’s Syndrome. Front Immunol. 2019 Jul 11:10:1600. doi: 10.3389/fimmu.2019.01600. eCollection 2019.Seeliger T, Prenzler NK, Gingele S, et al. Neuro-Sjцgren: Peripheral Neuropathy With Limb Weakness in Sjцgren’s Syndrome. Front Immunol. 2019 Jul 11:10:1600. doi: 10.3389/fimmu.2019.01600. eCollection 2019.Mehmood M, Jog A, Niazi M, et al. Atypical 's syndrome initially presenting as lymphocytic interstitial pneumonitis followed by immune thrombocytopenia. Case Rep Rheumatol. 2021 Mar 15;2021:6681590. doi: 10.1155/2021/6681590.Mehmood M, Jog A, Niazi M, et al. Atypical 's syndrome initially presenting as lymphocytic interstitial pneumonitis followed by immune thrombocytopenia. Case Rep Rheumatol. 2021 Mar 15;2021:6681590. doi: 10.1155/2021/6681590.Noh G, Han CW. Intravenous Immune Globulin (IVIG) Therapy After Unsuccessful Treatment with Corticosteroid and Cyclosporine A in Pfeifer-Weber-Christian Disease: A Case Report. Am J Case Rep. 2021 Jan 4; 22:e929519. doi: 10.12659/AJCR.929519Noh G, Han CW. Intravenous Immune Globulin (IVIG) Therapy After Unsuccessful Treatment with Corticosteroid and Cyclosporine A in Pfeifer-Weber-Christian Disease: A Case Report. Am J Case Rep. 2021 Jan 4; 22:e929519. doi: 10.12659/AJCR.929519Shen X, Wang F. The additional treatment value of immunoglobulin for the treatment of rheumatoid arthritis complicated with interstitial lung disease: A propensity score-matched pilot study. Int J Rheum Dis. 2023 Sep; 26(9):1745-1750. doi: 10.1111/1756-185X.14808.Shen X, Wang F. The additional treatment value of immunoglobulin for the treatment of rheumatoid arthritis complicated with interstitial lung disease: A propensity score-matched pilot study. Int J Rheum Dis. 2023 Sep; 26(9):1745-1750. doi: 10.1111/1756-185X.14808.Katz-Agranov N, Khattri S, Zandman-Goddard G. The role of intravenous immunoglobulins in the treatment of rheumatoid arthritis. Autoimmun Rev. 2015 Aug; 14(8):651-8. doi: 10.1016/j.autrev.2015.04.003. Epub 2015 Apr 12.Katz-Agranov N, Khattri S, Zandman-Goddard G. The role of intravenous immunoglobulins in the treatment of rheumatoid arthritis. Autoimmun Rev. 2015 Aug; 14(8):651-8. doi: 10.1016/j.autrev.2015.04.003. Epub 2015 Apr 12.Muscat C, Bertotto A, Ercolani R, et al. Long term treatment of rheumatoid arthritis with high doses of intravenous immunoglobulins: effects on disease activity and serum cytokines. Ann Rheum Dis. 1995 May;54(5): 382-5. doi: 10.1136/ard.54.5.382.Muscat C, Bertotto A, Ercolani R, et al. Long term treatment of rheumatoid arthritis with high doses of intravenous immunoglobulins: effects on disease activity and serum cytokines. Ann Rheum Dis. 1995 May;54(5): 382-5. doi: 10.1136/ard.54.5.382.Kanik KS, Yarboro CH, Naparstek Y, et al. Failure of low-dose intravenous immunoglobulin therapy to suppress disease activity in patients with treatment-refractory rheumatoid arthritis. Arthritis Rheum. 1996 Jun;39(6): 1027-9. doi: 10.1002/art.1780390621.Kanik KS, Yarboro CH, Naparstek Y, et al. Failure of low-dose intravenous immunoglobulin therapy to suppress disease activity in patients with treatment-refractory rheumatoid arthritis. Arthritis Rheum. 1996 Jun;39(6): 1027-9. doi: 10.1002/art.1780390621.Maksymowych WP, Avina-Zubieta A, Luong M, Russell AS. High dose intravenous immunoglobulin (IVIG) in severe refractory rheumatoid arthritis: no evidence for efficacy. Clin Exp Rheumatol. 1996 Nov-Dec;14(6): 657-60.Maksymowych WP, Avina-Zubieta A, Luong M, Russell AS. High dose intravenous immunoglobulin (IVIG) in severe refractory rheumatoid arthritis: no evidence for efficacy. Clin Exp Rheumatol. 1996 Nov-Dec;14(6): 657-60.Silverman ED, Cawkwell GD, Lovell DJ, et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. Pediatric Rheumatology Collaborative Study Group. J Rheumatol. 1994 Dec;21(12):2353-8.Silverman ED, Cawkwell GD, Lovell DJ, et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. Pediatric Rheumatology Collaborative Study Group. J Rheumatol. 1994 Dec;21(12):2353-8.

The authors declare that there are no conflicts of interest present.